Ambroxol as a novel disease-modifying treatment for Parkinson’s disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial

Ambroxol as a novel disease-modifying treatment for Parkinson’s disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial

Abstract Background Currently there are no disease-modifying treatments for Parkinson’s disease dementia (PDD), a condition linked to aggregation of the protein α-synuclein in subcortical and cortical brain areas. One of the leading genetic risk factors for Parkinson's disease is being a carrie...

Full description

Bibliographic Details
Main Authors: C. R. A. Silveira, J. MacKinley, K. Coleman, Z. Li, E. Finger, R. Bartha, S. A. Morrow, J. Wells, M. Borrie, R. G. Tirona, C. A. Rupar, G. Zou, R. A. Hegele, D. Mahuran, P. MacDonald, M. E. Jenkins, M. Jog, S. H. Pasternak
Format: Article
Language:English
Published: BMC 2019-02-01
Series:BMC Neurology
Subjects:
Parkinson’s disease dementia
α-Synuclein
Glucocerebrosidase
Ambroxol
Cognition
Online Access:http://link.springer.com/article/10.1186/s12883-019-1252-3

Internet

http://link.springer.com/article/10.1186/s12883-019-1252-3

Similar Items